These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34637857)

  • 1. Reduced expression of dopamine D2 receptors on astrocytes in R6/1 HD mice and HD post-mortem tissue.
    Harris KL; Mason SL; Vallin B; Barker RA
    Neurosci Lett; 2022 Jan; 767():136289. PubMed ID: 34637857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.
    Dallérac GM; Cummings DM; Hirst MC; Milnerwood AJ; Murphy KP
    Neuromolecular Med; 2016 Mar; 18(1):146-53. PubMed ID: 26782175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
    Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA
    Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum.
    Vetter JM; Jehle T; Heinemeyer J; Franz P; Behrens PF; Jackisch R; Landwehrmeyer GB; Feuerstein TJ
    J Neurochem; 2003 May; 85(4):1054-63. PubMed ID: 12716437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease.
    Spektor BS; Miller DW; Hollingsworth ZR; Kaneko YA; Solano SM; Johnson JM; Penney JB; Young AB; Luthi-Carter R
    Brain Res Mol Brain Res; 2002 Jun; 102(1-2):118-28. PubMed ID: 12191502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
    Hickey MA; Reynolds GP; Morton AJ
    J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.
    Björkqvist M; Petersén A; Bacos K; Isaacs J; Norlén P; Gil J; Popovic N; Sundler F; Bates GP; Tabrizi SJ; Brundin P; Mulder H
    Hum Mol Genet; 2006 May; 15(10):1713-21. PubMed ID: 16613897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early defect of transforming growth factor β1 formation in Huntington's disease.
    Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
    J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions.
    L'Episcopo F; Drouin-Ouellet J; Tirolo C; Pulvirenti A; Giugno R; Testa N; Caniglia S; Serapide MF; Cisbani G; Barker RA; Cicchetti F; Marchetti B
    Cell Death Dis; 2016 Apr; 7(4):e2206. PubMed ID: 27124580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal neurochemical changes in transgenic models of Huntington's disease.
    Ariano MA; Aronin N; Difiglia M; Tagle DA; Sibley DR; Leavitt BR; Hayden MR; Levine MS
    J Neurosci Res; 2002 Jun; 68(6):716-29. PubMed ID: 12111832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.
    Faideau M; Kim J; Cormier K; Gilmore R; Welch M; Auregan G; Dufour N; Guillermier M; Brouillet E; Hantraye P; Déglon N; Ferrante RJ; Bonvento G
    Hum Mol Genet; 2010 Aug; 19(15):3053-67. PubMed ID: 20494921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
    J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
    Renoir T; Argyropoulos A; Chevarin C; Lanfumey L; Hannan AJ
    Pharmacol Biochem Behav; 2014 Dec; 127():15-20. PubMed ID: 25316307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous dopamine receptor changes in early and late Huntington's disease.
    Richfield EK; O'Brien CF; Eskin T; Shoulson I
    Neurosci Lett; 1991 Oct; 132(1):121-6. PubMed ID: 1838580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
    Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
    Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
    Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.